Información del artículo
Resumen
En esta formación continuada se analizan los recientes avances en Medicina Nuclear centrados en el desarrollo de nuevos radiofármacos que mejoran tanto el diagnóstico como el tratamiento de enfermedades complejas. Destaca la teragnosis, que combina diagnóstico y tratamiento mediante pares de radiofármacos dirigidos a una misma diana molecular, lo que permite personalizar los tratamientos.
En esta primera parte se revisan específicamente los pares teragnósticos cobre-64/cobre-67, plomo-212/plomo-203 y escandio-44/escandio-47, resaltando sus características físicas, métodos de obtención y potenciales aplicaciones clínicas.
A pesar de los desafíos en su producción, su versatilidad y efectividad están impulsando su aplicación clínica en oncología y otras enfermedades. El texto también aborda el desarrollo de nuevos radiofármacos y su impacto en la medicina de precisión, señalando las futuras direcciones y oportunidades de investigación en este campo.
Palabras clave:
Radionúclidos
Pares teragnósticos
Radiofármacos
Imagen molecular
Terapia personalizada
Abstract
This continuing education analyzes recent advances in Nuclear Medicine focused on the development of new radiopharmaceuticals that improve both the diagnosis and treatment of complex diseases. The focus is on teragnosis, which combines diagnosis and treatment by means of pairs of radiopharmaceuticals directed to the same molecular target, which allows the personalization of treatments.
This first part specifically reviews the teragnostic pairs copper-64/copper-67, lead-212/lead-203 and scandium-44/scandium-47, highlighting their physical characteristics, methods of production and potential clinical applications.
Despite the challenges in their production, their versatility and effectiveness are driving their clinical application in oncology and other diseases. The text also addresses the development of new radiopharmaceuticals and their impact on precision medicine, pointing out future directions and opportunities for research in this field.
Keywords:
Radionuclides
Diagnostic pairs
Radiopharmaceuticals
Molecular imaging
Personalised therapy
Artículo
Opciones para acceder a los textos completos de la publicación Revista Española de Medicina Nuclear e Imagen Molecular
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
J.C. Alonso, J. Orcajo.
Terapia Radiometabólica. Teragnosis.
1.a ed., Aula Médica, (2023),
[2]
M. Jauregui-Osoro, S. De Robertis, P. Halsted, S.M. Gould, Z. Yu, R.L. Paul, et al.
Production of copper-64 using a hospital cyclotron: Targetry, purification and quality analysis.
Nucl Med Commun., 42 (2021), pp. 1024-1038
[3]
O.O. Krasnovskaya, D. Abramchuck, A. Erofeev, P. Gorelkin, A. Kuznetsov, A. Shemukhin, et al.
Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals.
Int J Mol Sci., 24 (2023), pp. 9154
[4]
A. Jha, M. Patel, J.A. Carrasquillo, C.C. Chen, C. Millo, R. Maass-Moreno, et al.
Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE.
J. Nucl. Med., 63 (2022), pp. 1300-1301
[5]
International Atomic Energy Agency.
Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications.
IAEA, (2022),
[6]
J. Bolcaen, M.A. Gizawy, S.Y.A. Terry, A. Paulo, B. Cornelissen, A. Korde, et al.
Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy.
J Nucl Med., 64 (2023), pp. 1344-1351
[7]
L. Mou, P. Martini, G. Pupillo, I. Cieszykowska, C.S. Cutler, R. Mikołajczak.
67Cu Production Capabilities: A Mini Review.
Molecules., 27 (2022), pp. 1501
[8]
M.J. Merrick, D.A. Rotsch, A. Tiwari, J. Nolen, T. Brossard, J. Song, et al.
Imaging and dosimetric characteristics of 67 Cu.
Phys Med Biol., 66 (2021), pp. 035002
[9]
F. Peng.
Recent Advances in Cancer Imaging with 64CuCl2 PET/CT.
Nucl Med Mol Imaging., 56 (2022), pp. 80-85
[10]
M.T. Kuo, S. Fu, N. Savaraj, H.H.W. Chen.
Role of the Human High-Affinity Copper Transporter in Copper Homeostasis Regulation and Cisplatin Sensitivity in Cancer Chemotherapy.
Cancer Res., 72 (2012), pp. 4616-4621
[11]
A. Piccardo, F. Paparo, M. Puntoni, S. Righi, G. Bottoni, L. Bacigalupo, et al.
64 CuCl 2 PET/CT in Prostate Cancer Relapse.
J Nucl Med., 59 (2018), pp. 444-451
[12]
M. Mascia, C. Villano, V. De Francesco, L. Schips, M. Marchioni, L. Cindolo.
Efficacy and Safety of the 64Cu(II)Cl2 PET/CT for Urological Malignancies.
Clin Nucl Med., 46 (2021), pp. 443-448
[13]
F. Fiz, G. Bottoni, M. Ugolini, S. Righi, A. Cirone, M.C. Garganese, et al.
Diagnostic and Dosimetry Features of [64Cu]CuCl2 in High-Grade Paediatric Infiltrative Gliomas.
Mol Imaging Biol., 25 (2023), pp. 391-400
[14]
F.O. García-Pérez, S.S. Medina-Ornelas, F. Barron-Barron, O. Arrieta-Rodriguez.
Evaluation of non-small cell lung cancer by PET/CT with 64CuCl2: initial experience in humans.
Am J Nucl Med Mol Imaging., 10 (2020), pp. 143-150
[15]
D. Moreno, O. Murillo, C. Gazquez, R. Hernandez-Alcoceba, R. Uerlings, G. Gonzalez-Aseguinolaza, et al.
Visualization of the therapeutic efficacy of a gene correction approach in Wilson's disease by laser-ablation inductively coupled mass spectrometry.
J Hepatol., 68 (2018), pp. 1088-1090
[16]
O. Murillo, D. Moreno, C. Gazquez, M. Barberia, I. Cenzano, I. Navarro, et al.
Liver Expression of a MiniATP7B Gene Results in Long-Term Restoration of Copper Homeostasis in a Wilson Disease Model in Mice.
Hepatology., 70 (2019), pp. 108-126
[17]
O. Murillo, M. Collantes, C. Gazquez, D. Moreno, R. Hernandez-Alcoceba, M. Barberia, et al.
High value of 64Cu as a tool to evaluate the restoration of physiological copper excretion after gene therapy in Wilson's disease.
Mol Ther Methods Clin Dev., 26 (2022), pp. 98-106
[18]
E.A. Carlsen, C.B. Johnbeck, T. Binderup, M. Loft, A. Pfeifer, J. Mortensen, et al.
64 Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms.
J Nucl Med., 61 (2020), pp. 1491-1497
[19]
L. Urso, A. Nieri, L. Uccelli, A. Castello, P. Artioli, C. Cittanti, et al.
Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.
Pharmaceutics., 15 (2023), pp. 1110
[20]
C.B. Johnbeck, U. Knigge, A. Loft, A.K. Berthelsen, J. Mortensen, P. Oturai, et al.
Head-to-Head Comparison of 64 Cu-DOTATATE and 68 Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
J Nucl Med., 58 (2017), pp. 451-457
[21]
A.E. Machulkin, Y.A. Ivanenkov, A.V. Aladinskaya, M.S. Veselov, V.A. Aladinskiy, E.K. Beloglazkina, et al.
Small-molecule PSMA ligands. Current state, SAR and perspectives.
J Drug Target., 24 (2016), pp. 679-693
[22]
D.R. Cardoza-Ochoa, B. Rivera-Bravo.
A Comparison of 18F-PSMA-1007 and 64Cu-PSMA in 2 Patients With Metastatic Prostate Cancer.
Clin Nucl Med., 47 (2022), pp. e120-e122
[23]
M. Xu, Y. Han, G. Liu, Y. Xu, D. Duan, H. Liu, et al.
Preclinical Study of a Fully Human Anti-PD-L1 Antibody as a Theranostic Agent for Cancer Immunotherapy.
Mol Pharm., 15 (2018), pp. 4426-4433
[24]
W. Lee, S. Sarkar, R. Pal, J.Y. Kim, H. Park, P.T. Huynh, et al.
Successful Application of CuAAC Click Reaction in Constructing 64 Cu-Labeled Antibody Conjugates for Immuno-PET Imaging.
ACS Appl Bio Mater., 4 (2021), pp. 2544-2557
[25]
O. Keinänen, K. Fung, J.M. Brennan, N. Zia, M. Harris, E. van Dam, et al.
Harnessing 64 Cu/67 Cu for a theranostic approach to pretargeted radioimmunotherapy.
Proc Natl Acad Sci U S A., 117 (2020), pp. 28316-28327
[26]
M. Li, E.A. Sagastume, D. Lee, D. McAlister, A.J. DeGraffenreid, K.R. Olewine, et al.
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer.
Curr Med Chem., 27 (2020), pp. 7003-7031
[27]
A. Ingham, T.I. Kostelnik, B.L. McNeil, B.O. Patrick, N. Choudhary, M. Jaraquemada-Peláez, et al.
Getting a lead on Pb 2+-amide chelators for 203/212 Pb radiopharmaceuticals.
Dalton Trans., 50 (2021), pp. 11579-11595
[28]
M.W. Brechbiel.
Bifunctional chelates for metal nuclides.
Q J Nucl Med Mol Imaging, 52 (2008), pp. 166-173
[29]
L.L. Chappell, E. Dadachova, D.E. Milenic, K. Garmestani, C. Wu, M.W. Brechbiel.
Synthesis, characterization, and evaluation of a novel bifunctional chelating agent for the lead isotopes 203Pb and 212Pb.
Nucl Med Biol., 27 (2000), pp. 93-100
[30]
S.R. Banerjee, I. Minn, V. Kumar, A. Josefsson, A. Lisok, M. Brummet, et al.
Preclinical Evaluation of 203/212 Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer.
J Nucl Med., 61 (2020), pp. 80-88
[31]
V.Y. Stenberg, A. Juzeniene, Q. Chen, X. Yang, Bruland ØS, R.H. Larsen.
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [212 Pb]Pb-NG001 for prostate cancer.
J Labelled Comp Radiopharm., 63 (2020), pp. 129-143
[32]
J.C. Dos Santos, M. Schäfer, U. Bauder-Wüst, W. Lehnert, K. Leotta, A. Morgenstern, et al.
Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?.
Eur J Nucl Med Mol Imaging., 46 (2019), pp. 1081-1091
[33]
V.Y. Stenberg, R.H. Larsen, L.-W. Ma, Q. Peng, P. Juzenas, Bruland ØS, et al.
Evaluation of the PSMA-Binding Ligand 212Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer.
Int J Mol Sci., 22 (2021), pp. 4815
[34]
R. Montironi, R. Mazzucchelli, F. Barbisan, D. Stramazzotti, A. Santinelli, M. Scarpelli, et al.
HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer.
Hum Pathol., 37 (2006), pp. 1137-1144
[35]
Z. Tan, P. Chen, N. Schneider, S. Glover, L. Cui, J. Torgue, et al.
Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice.
Int J Oncol., 40 (2012), pp. 1881-1888
[36]
V. Boudousq, L. Bobyk, M. Busson, V. Garambois, M. Jarlier, P. Charalambatou, et al.
Comparison between Internalizing Anti-HER2 mAbs and Non-Internalizing Anti-CEA mAbs in Alpha-Radioimmunotherapy of Small Volume Peritoneal Carcinomatosis Using 212Pb.
PLoS One., 8 (2013), pp. e69613
[37]
S. Westrøm, R. Generalov, T.B. Bønsdorff, R.H. Larsen.
Preparation of 212 Pb-labeled monoclonal antibody using a novel 224 Ra-based generator solution.
Nucl Med Biol., 51 (2017), pp. 1-9
[38]
K. Yong, M. Brechbiel.
Application of 212Pb for Targeted α-particle Therapy (TAT): Pre-clinical and Mechanistic Understanding through to Clinical Translation.
AIMS Med Sci., 2 (2015), pp. 228-245
[39]
Y. Miao, S.D. Figueroa, D.R. Fisher, H.A. Moore, R.F. Testa, T.J. Hoffman, et al.
203 Pb-Labeled α-Melanocyte–Stimulating Hormone Peptide as an Imaging Probe for Melanoma Detection.
J Nucl Med., 49 (2008), pp. 823-829
[40]
J. Yang, J. Xu, R. Gonzalez, T. Lindner, C. Kratochwil, Y. Miao.
68 Ga-DOTA-GGNle-CycMSH hex targets the melanocortin-1 receptor for melanoma imaging.
Sci Transl Med., 10 (2018),
[41]
Z.S. Morris, M. Puhlmann, F. Johnson, A. Hanna, S.Y. Cho.
A phase I/IIa of [212 Pb]VMT01 targeted a-particle therapy for unresectable or metastatic melanoma.
J Clin Oncol., 42 (2024),
[42]
T.A.R. Stallons, A. Saidi, I. Tworowska, E.S. Delpassand, J.J. Torgue.
Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.
Mol Cancer Ther., 18 (2019), pp. 1012-1021
[43]
E.S. Delpassand, I. Tworowska, R. Esfandiari, J. Torgue, J. Hurt, A. Shafie, et al.
Targeted α-Emitter Therapy with 212 Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
J Nucl Med., 63 (2022), pp. 1326-1333
[44]
N. Okoye, T. Rold, A. Berendzen, X. Zhang, R. White, M. Schultz, et al.
Targeting the BB2 receptor in prostate cancer using a Pb-203 labeled peptide.
J Nucl Med., 58 (2017), pp. 321
[45]
B.B. Kasten, R.C. Arend, A.A. Katre, H. Kim, J. Fan, S. Ferrone, et al.
B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models.
Nucl Med Biol., 47 (2017), pp. 23-30
[46]
I. Ioannidis, G. Lefkaritis, S.N. Georgiades, I. Pashalidis, G.J. Kontoghiorghes.
Towards Clinical Development of Scandium Radioisotope Complexes for Use in Nuclear Medicine: Encouraging Prospects with the Chelator 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic Acid (DOTA) and Its Analogues.
Int J Mol Sci., 25 (2024), pp. 5954
[47]
F. Rosar, H. Bohnenberger, E.S. Moon, F. Rösch, A. Denig, D. Vincenz-Zörner, et al.
Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems.
Appl Radiat Isot., 170 (2021), pp. 109599
[48]
T.V.M. Lima, S. Gnesin, K. Strobel, M. Pérez, J.E. Roos, C. Müller, et al.
Fifty Shades of Scandium: Comparative Study of PET Capabilities Using Sc-43 and Sc-44 with Respect to Conventional Clinical Radionuclides.
Diagnostics., 11 (2021), pp. 1826
[49]
C.E. Schmidt, L. Gajecki, M.A. Deri, V.A. Sanders.
Current State of 44Ti/44Sc Radionuclide Generator Systems and Separation Chemistry.
Curr Radiopharm., 16 (2023), pp. 95-106
[50]
D. Pawlak, W. Wojdowska, L.J. Parus, I. Cieszykowska, M. Zoltowska, P. Garnuszek, et al.
Comparison of separation methods for 47Ca/47Sc radionuclide generator.
Appl Radiat Isot., 151 (2019), pp. 140-144
[51]
G. Trencsényi, Z. Képes.
Scandium-44: Diagnostic Feasibility in Tumor-Related Angiogenesis.
Int J Mol Sci., 24 (2023), pp. 7400
[52]
N. Viola-Villegas, R.P. Doyle.
The coordination chemistry of 1,4,7 10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid (H4DOTA): Structural overview and analyses on structure–stability relationships.
Coord Chem Rev., 253 (2009), pp. 1906-1925
[53]
A. Majkowska-Pilip, A. Bilewicz.
Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals.
J Inorg Biochem., 105 (2011), pp. 313-320
[54]
M. Pruszyński, A. Majkowska-Pilip, N.S. Loktionova, E. Eppard, F. Roesch.
Radiolabeling of DOTATOC with the long-lived positron emitter 44Sc.
Appl Radiat Isot., 70 (2012), pp. 974-979
[55]
A. Singh, N.P. van der Meulen, C. Müller, I. Klette, H.R. Kulkarni, A. Türler, et al.
First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced 44 Sc-DOTATOC: A Proof-of-Concept Study.
Cancer Biother Radiopharm., 32 (2017), pp. 124-132
[56]
H. Javid, M.A. Oryani, N. Rezagholinejad, A. Esparham, M. Tajaldini, M. Karimi-Shahri, et al.
RGD peptide in cancer targeting: Benefits, challenges, solutions, and possible integrin–RGD interactions.
Cancer Med., 13 (2024), pp. e6800
[57]
R. Hernandez, H.F. Valdovinos, Y. Yang, R. Chakravarty, H. Hong, T.E. Barnhart, et al.
44Sc: An Attractive Isotope for Peptide-Based PET Imaging.
Mol Pharm., 11 (2014), pp. 2954-2961
[58]
K.A. Domnanich, C. Müller, R. Farkas, R.M. Schmid, B. Ponsard, R. Schibli, et al.
44Sc for labeling of DOTA- and NODAGA-functionalized peptides: preclinical in vitro and in vivo investigations.
EJNMMI Radiopharm Chem., 1 (2017), pp. 8
[59]
R. Mansi, R. Minamimoto, H. Mäcke, A.H. Iagaru.
Bombesin-Targeted PET of Prostate Cancer.
J Nucl Med., 57 (2016), pp. 67S-72S
[60]
E. Koumarianou, N.S. Loktionova, M. Fellner, F. Roesch, O. Thews, D. Pawlak, et al.
44Sc-DOTA-BN[2-14]NH2 in comparison to 68Ga-DOTA-BN[2-14]NH2 in pre-clinical investigation. Is 44Sc a potential radionuclide for PET?.
Appl Radiat Isot., 70 (2012), pp. 2669-2676
[61]
E. Eppard, A. de la Fuente, M. Benešová, A. Khawar, R.A. Bundschuh, F.C. Gärtner, et al.
Clinical Translation and First In-Human Use of [44 Sc]Sc-PSMA-617 for PET Imaging of Metastasized Castrate-Resistant Prostate Cancer.
Theranostics., 7 (2017), pp. 4359-4369
[62]
B.A. Vaughn, A.J. Koller, Z. Chen, S.H. Ahn, C.S. Loveless, S.J. Cingoranelli, et al.
Homologous Structural Chemical, and Biological Behavior of Sc and Lu Complexes of the Picaga Bifunctional Chelator: Toward Development of Matched Theranostic Pairs for Radiopharmaceutical Applications.
Bioconjug Chem., 32 (2021), pp. 1232-1241
[63]
B.A. Vaughn, S.H. Ahn, E. Aluicio-Sarduy, J. Devaraj, A.P. Olson, J. Engle, et al.
Chelation with a twist: a bifunctional chelator to enable room temperature radiolabeling and targeted PET imaging with scandium-44.
Chem Sci., 11 (2020), pp. 333-342
[64]
B.A. Vaughn, C.S. Loveless, S.J. Cingoranelli, D. Schlyer, S.E. Lapi, E. Boros.
Evaluation of 177 Lu and 47 Sc Picaga-Linked Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry.
Mol Pharm., 18 (2021), pp. 4511-4519
[65]
A. Challapalli, L. Carroll, E.O. Aboagye.
Molecular mechanisms of hypoxia in cancer.
Clin Transl Imaging., 5 (2017), pp. 225-253
[66]
D. Szücs, T. Csupász, J.P. Szabó, A. Kis, B. Gyuricza, V. Arató, et al.
Synthesis, Physicochemical Labeling and In Vivo Characterization of 44Sc-Labeled DO3AM-NI as a Hypoxia-Sensitive PET Probe.
Pharmaceuticals., 15 (2022), pp. 666
[67]
S.-D. Liu, L.-P. Zhong, J. He, Y.-X. Zhao.
Targeting neuropilin-1 interactions is a promising anti-tumor strategy.
Chin Med J (Engl)., 134 (2021), pp. 508-517
[68]
K. Masłowska, P. Redkiewicz, P.K. Halik, E. Witkowska, D. Tymecka, R. Walczak, et al.
Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy.
Biomedicines., 11 (2023), pp. 564
